Suppliers / Senador Laboratories

Senador Laboratories

India 3 duplicate records merged Updated 9 July 2026

Senador Laboratories is a finished-dose manufacturer based in India. It appears in 39 regulatory filings across 6 regulators, without an active US DMF or CEP on file. Its filings concentrate with MCAZ (ZW), EFDA (ET) and ARCSA (EC). Its GMP standing is certified by EMA and ANVISA (Brazil). Its most recent recorded inspection, by US FDA, closed on 16 September 2019 as NAI. Customs aggregates show $71.5M of exports covering 831 molecules to 99 destinations in 2025.

0
active US DMFs
0
valid CEPs
3
registered plants 1 with an FDA FEI number
39
filings across 6 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
5 of 5 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 16 September 2019 NAI US FDA
  • 24 November 2017 NAI US FDA
  • 29 August 2017 NAI US FDA
  • 25 July 2014 NAI US FDA
  • 28 June 2012 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
AHMEDABAD, India Not on file
Sarigam, India Not on file
Ahmedabad, India 3008725987

Filings and GMP by regulator

Regulator Filings GMP certificates
MCAZ (ZW) 12 None
EFDA (ET) 8 None
ARCSA (EC) 8 None
TMDA (TZ) 5 None
ZAMRA (ZM) 4 None
MINSA (CR) 2 None
EMA None 4
ANVISA (Brazil) None 1

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $7.7M 35
2025 Not reported $71.5M 99
2024 Not reported $41.9M 74

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Senador Laboratories comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 16 September 2019.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts